Skip to search formSkip to main contentSkip to account menu

motesanib

An orally bioavailable receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits vascular… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Imetelstat
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibitionmotesanib diphosphate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
Clinical evidence shows that dual inhibition of kinases as well angiogenesis provides ideal therapeutic option in the treatment… 
Review
2012
Review
2012
Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer.
Review
2012
Review
2012
Novel molecular targeted therapies for refractory thyroid cancer
The incidence of thyroid cancer continues to increase and this neoplasia remains the most common endocrine malignancy. No… 
2012
2012
Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study.
Since the discovery of the critical role played by angiogenesis in tumor growth and development (1), there has been increased… 
Review
2011
Review
2011
Motesanib and advanced NSCLC: experiences and expectations
Introduction: Benefits from conventional chemotherapy in NSCLC have plateaued. Accordingly, sizeable efforts have gone into… 
Review
2010
Review
2010
Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC).
7528 Background: Motesanib is a small molecule antagonist of VEGF (1, 2, and 3), PDGF, and Kit receptors. The objective of this… 
2010
2010
Augmentation of Radiation Response by Motesanib, a Multikinase Inhibitor that Targets Vascular Endothelial Growth Factor Receptors
Background: Motesanib is a potent inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, platelet-derived… 
2010
2010
Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC).
3538 Background: Motesanib is an oral inhibitor of VEGF, PDFG, and Kit receptors. Pmab, a fully human monoclonal antibody against… 
Review
2009
Review
2009
Novel treatment of medullary thyroid cancer
Purpose of reviewMetastatic medullary thyroid cancer (MTC) is an incurable disease once metastasis becomes unresectable. Many… 
Review
2009
Review
2009
CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC).
Background: We assessed, in a double-blinded placebo-controlled trial, the effect of adding motesanib (M), a small molecule… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)